PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10

Reported: September 17, 2025 Initiated: August 8, 2025 #D-0621-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10

Reason for Recall

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.

Details

Units Affected
3,591 bottles
Distribution
AZ, IN, NJ
Location
Berkeley Heights, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10. Recalled by Breckenridge Pharmaceutical, Inc.. Units affected: 3,591 bottles.
Why was this product recalled?
CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 17, 2025. Severity: Moderate. Recall number: D-0621-2025.